Ostatní
Návod 
Exelixis, Inc.
EXEL
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
10.8B
Obrat
2B
Zisk
1B
Aktiva
3B
Dluh
0B
ROE
0%
ROA
0%
PE
15
PS
5
Cena 1R
32-50
⌀ Cena
40.74
Dividenda
0.0(0.0%)
Čtvrtletní 10-Q
Celoroční 10-K
Nadcházející oznámení zisků
10-02-2026
Poslední dividenda
Profil
Exelixis, Inc., biotechnologická společnost zaměřená na onkologii, se zaměřuje na objevování, vývoj a komercializaci nových léků pro léčbu rakoviny ve Spojených státech. Mezi produkty společnosti patří tablety CABOMETYX pro léčbu pacientů s pokročilým karcinomem ledvin, kteří byli již dříve léčeni antiangiogenními léky, a tobolky COMETRIQ pro léčbu pacientů s progresivním a metastazujícím medulárním karcinomem štítné žlázy. Jeho CABOMETYX a COMETRIQ jsou odvozeny z kabozantinibu, inhibitoru mnohočetných tyrosinkináz, včetně receptorů MET, AXL, RET a VEGF. Společnost také nabízí COTELLIC, inhibitor MEK jako kombinovaný režim pro léčbu pokročilého melanomu, a MINNEBRO, perorální nesteroidní selektivní blokátor mineralokortikoidního receptoru pro léčbu hypertenze v Japonsku. Kromě toho vyvíjí XL092, perorální inhibitor tyrosinkinázy, který se zaměřuje na VEGF receptory, MET, AXL, MER a další kinázy podílející se na růstu a šíření rakoviny; XB002, konjugát protilátek a léků složený z lidského mAb proti tkáňovému faktoru (TF) pro léčbu pokročilých solidních nádorů; XL102, perorálně biologicky dostupný inhibitor cyklin-dependentní kinázy 7 (CDK7) pro léčbu pokročilých nebo metastazujících solidních nádorů; a XB002 pro léčbu non-hodgkinova lymfomu. Společnost Exelixis, Inc. spolupracuje na výzkumu a uzavírá licenční smlouvy se společností Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Bristonesty l-Myers Squibb Company a Daiichi Sankyo Company Limited. Společnost byla dříve známá jako Exelixis Pharmaceuticals, Inc. a v únoru 2000 změnila svůj název na Exelixis, Inc. Společnost Exelixis, Inc. byla založena v roce 1994 a sídlí v Alamedě v Kalifornii.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
1147
Založení
2000-04-17
Podobné společnosti
$ 52.17
+ $ 0.71
$ 23.89
- $ 0.66
$ 62.37
+ $ 1.36
$ 57.36
- $ 0.05
$ 68.88
+ $ 0.64
$ 487.29
- $ 1.97
$ 69.78
- $ 0.06
Zahraniční články
Výsledovka
Rozvaha
Peněžní toky
Výsledovka
Výsledovka
Rozvaha
Peněžní toky
V miliónech (USD)
| Revenue | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 2,320.1 | 2,320.1 | 2,168.7 | 1,830.2 | 1,611.1 | 1,435.0 | 987.5 | 967.8 | 853.8 | 452.5 | 191.5 | 37.2 | 25.1 | 31.3 | 47.5 | 289.6 | 185.0 | |
| Cost of Revenues | 83.7 | 83.7 | 76.2 | 72.5 | 57.9 | 52.9 | 36.3 | 33.1 | 26.3 | 15.1 | 6.6 | 3.9 | 2.0 | 1.1 | 0.0 | 0.0 | 0.0 | |
| Gross Profit | 2,236.4 | 2,236.4 | 2,092.5 | 1,757.7 | 1,553.2 | 1,382.1 | 951.3 | 934.7 | 827.5 | 437.4 | 184.9 | 33.3 | 23.1 | 30.2 | 47.5 | 289.6 | 185.0 |
| Revenue | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenues | 598.7 | 597.8 | 568.3 | 555.4 | 566.8 | 539.5 | 637.2 | 425.2 | 479.7 | 471.9 | |
| Cost of Revenues | 26.5 | 18.6 | 19.5 | 19.2 | 20.0 | 17.3 | 17.7 | 21.3 | 21.8 | 18.8 | |
| Gross Profit | 572.2 | 579.2 | 548.8 | 536.3 | 546.8 | 522.2 | 619.5 | 404.0 | 457.9 | 453.1 |
| Operating Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 1,044.1 | 891.8 | 693.7 | 547.9 | 337.0 | 182.3 | 112.2 | 96.0 | 96.4 | 189.1 | 178.8 | 128.9 | 156.8 | 210.7 | |
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 542.7 | 459.9 | 401.7 | 293.4 | 228.2 | 206.4 | 159.4 | 116.1 | 57.3 | 50.8 | 51.0 | 31.8 | 33.1 | 33.0 | |
| Depreciation & Amortization | 29.1 | 29.1 | 28.8 | 25.7 | 20.9 | 13.6 | 9.1 | 8.3 | 7.8 | 1.2 | 1.0 | 1.4 | 2.4 | 3.1 | 5.7 | 6.8 | 10.5 | |
| Total Operating Expenses | 1,364.2 | 1,364.2 | 1,487.9 | 1,586.8 | 1,351.7 | 1,095.4 | 841.2 | 565.2 | 388.6 | 271.5 | 212.1 | 153.7 | 239.9 | 229.7 | 160.7 | 190.0 | 243.7 | |
| Operating Income | 872.2 | 872.2 | 604.6 | 170.9 | 201.5 | 286.7 | 110.1 | 369.5 | 438.9 | 165.9 | -28.1 | -121.4 | -224.5 | -200.7 | -122.4 | 89.5 | -91.4 |
| Operating Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| R&D Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 244.7 | 332.6 | ||
| Selling General & Admin Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 131.4 | 138.1 | ||
| Depreciation & Amortization | 6.9 | 7.4 | 7.3 | 7.3 | 7.6 | 7.5 | 7.3 | 6.4 | 6.5 | 6.3 | ||
| Total Operating Expenses | 337.0 | 342.6 | 335.2 | 349.4 | 383.6 | 386.1 | 343.6 | 374.5 | 376.1 | 470.7 | ||
| Operating Income | 235.2 | 236.5 | 213.6 | 186.9 | 163.2 | 136.1 | 275.9 | 29.5 | 81.8 | -17.6 |
| Net Income | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 69.2 | 69.2 | 77.2 | 86.5 | 33.1 | 7.7 | 19.9 | 28.0 | 12.8 | 4.9 | 4.9 | 0.4 | 4.3 | 1.2 | 2.0 | 1.5 | 0.1 | |
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | -53.7 | 0.0 | 0.0 | 0.0 | 0.0 | 8.7 | 33.1 | 48.7 | 48.6 | 45.3 | 27.1 | 16.3 | 9.3 | |
| Other Expense | 69.0 | 69.0 | 77.0 | 86.6 | 32.9 | 7.5 | 20.8 | 28.6 | 0.4 | -3.5 | -14.8 | -1.0 | -7.6 | -1.2 | -9.2 | -7.9 | -24.5 | |
| IBT | 941.2 | 941.2 | 681.6 | 257.5 | 234.4 | 294.2 | 130.8 | 398.1 | 452.1 | 158.6 | -70.2 | -169.7 | -268.7 | -244.9 | -147.5 | 77.0 | -92.4 | |
| Income Tax Expense | 158.6 | 158.6 | 160.4 | 49.8 | 52.1 | 63.1 | 19.1 | 77.1 | -238.0 | 4.4 | 32.1 | 0.1 | -0.2 | -0.1 | 0.1 | 1.3 | -0.1 | |
| Net Income | 782.6 | 782.6 | 521.3 | 207.8 | 182.3 | 231.1 | 111.8 | 321.0 | 690.1 | 154.2 | -70.2 | -169.7 | -268.5 | -244.8 | -147.6 | 75.7 | -92.3 |
| Net Income | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Interest Income | 17.4 | 15.9 | 16.8 | 19.1 | 21.3 | 18.7 | 17.3 | 19.9 | 21.4 | 23.1 | ||
| Interest Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 26.3 | 0.0 | ||
| Other Expense | 17.5 | 15.9 | 16.8 | 18.8 | 21.6 | 18.7 | 17.0 | 19.8 | 21.3 | 23.4 | ||
| IBT | 252.7 | 252.4 | 230.4 | 205.7 | 184.8 | 154.8 | 292.8 | 49.3 | 103.0 | 5.8 | ||
| Income Tax Expense | 8.2 | 58.8 | 45.6 | 46.1 | 44.9 | 36.8 | 66.7 | 12.0 | 17.5 | 4.8 | ||
| Net Income | 244.5 | 193.6 | 184.8 | 159.6 | 139.9 | 118.0 | 226.1 | 37.3 | 85.5 | 1.0 |
| Per Share Data | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.65 | $0.57 | $0.73 | $0.36 | $1.06 | $2.32 | $0.52 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.60 | $-0.85 | |
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.65 | $0.56 | $0.72 | $0.35 | $1.02 | $2.21 | $0.49 | $-0.28 | $-0.81 | $-1.38 | $-1.33 | $-0.92 | $0.58 | $-0.85 | |
| Shares Outstanding | 271.6 | 271.6 | 290.0 | 318.2 | 321.5 | 314.9 | 308.3 | 302.6 | 297.9 | 293.6 | 250.5 | 209.2 | 194.3 | 184.1 | 160.1 | 126.0 | 108.5 | |
| Diluted Shares Outstanding | 281.9 | 281.9 | 296.1 | 321.5 | 324.6 | 322.4 | 318.0 | 315.0 | 312.8 | 312.0 | 250.5 | 209.2 | 194.3 | 184.1 | 160.1 | 130.5 | 108.5 |
| Per Share Data | TTM | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EPS | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.28 | $0.00 | ||
| EPS Diluted | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.27 | $0.00 | ||
| Shares Outstanding | 271.6 | 268.4 | 272.6 | 278.8 | 284.5 | 285.6 | 289.2 | 300.8 | 308.5 | 315.5 | ||
| Diluted Shares Outstanding | 281.9 | 278.5 | 284.4 | 288.2 | 293.5 | 291.5 | 294.0 | 305.5 | 313.0 | 319.2 |
| Current Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 157.5 | 217.4 | 263.0 | 501.2 | 647.2 | 319.2 | 266.5 | 314.8 | 183.2 | 151.7 | 141.6 | 80.4 | 104.0 | 170.1 | 74.3 | 97.4 | |
| Short Term Investments | 844.5 | 893.9 | 732.3 | 807.3 | 819.9 | 887.3 | 585.7 | 378.6 | 204.6 | 268.1 | 25.4 | 63.9 | 138.5 | 241.4 | 120.0 | 65.2 | |
| Total Cash & ST Investments | 1,002.0 | 1,111.3 | 995.3 | 1,308.5 | 1,467.1 | 1,206.5 | 852.2 | 693.3 | 387.8 | 419.8 | 167.1 | 144.3 | 242.5 | 411.4 | 194.3 | 162.7 | |
| Accounts Receivable | 407.7 | 265.4 | 237.4 | 214.8 | 282.7 | 160.9 | 119.1 | 178.8 | 81.2 | 42.2 | 5.2 | 4.9 | 3.9 | 2.8 | 30.2 | 5.9 | |
| Inventory | 20.6 | 22.4 | 17.3 | 33.3 | 27.5 | 21.0 | 12.9 | 9.8 | 6.7 | 3.3 | 2.6 | 2.4 | 2.9 | 0.0 | 0.0 | 0.0 | |
| Other Current Assets | 47.1 | 68.5 | 67.9 | 62.2 | 57.5 | 57.0 | 27.0 | 15.0 | 9.3 | 47.7 | 3.8 | 15.7 | 17.3 | 18.4 | 4.4 | 14.9 | |
| Total Current Assets | 1,477.4 | 1,467.6 | 1,318.0 | 1,618.8 | 1,834.7 | 1,445.4 | 1,011.2 | 897.0 | 484.9 | 470.8 | 178.7 | 167.2 | 266.6 | 432.5 | 228.8 | 183.5 |
| Current Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash And Equivalents | 376.3 | 164.4 | 183.8 | 217.4 | 258.3 | 198.5 | 259.6 | 263.0 | 396.9 | 464.5 | |
| Short Term Investments | 612.2 | 626.7 | 847.6 | 893.9 | 930.8 | 803.5 | 703.7 | 732.3 | 706.5 | 802.3 | |
| Total Cash & ST Investments | 988.5 | 791.1 | 1,031.3 | 1,111.3 | 1,189.2 | 1,002.0 | 963.3 | 995.3 | 1,103.4 | 1,266.8 | |
| Accounts Receivable | 309.7 | 292.4 | 281.6 | 265.4 | 269.7 | 396.6 | 240.6 | 237.4 | 248.1 | 232.8 | |
| Inventory | 27.4 | 23.5 | 24.9 | 22.4 | 21.0 | 20.6 | 21.1 | 17.3 | 25.0 | 28.6 | |
| Other Current Assets | 76.6 | 73.8 | 58.7 | 68.5 | 69.8 | 58.2 | 67.5 | 67.9 | 66.9 | 62.3 | |
| Total Current Assets | 1,402.3 | 1,180.8 | 1,396.5 | 1,467.6 | 1,549.7 | 1,477.4 | 1,292.4 | 1,318.0 | 1,443.4 | 1,590.5 |
| Long-Term Assets | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 130.2 | 359.1 | 470.9 | 401.2 | 104.0 | 67.4 | 90.7 | 56.8 | 25.7 | 2.1 | 1.4 | 2.4 | 4.9 | 6.1 | 8.5 | 15.8 | |
| Goodwill | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 433.8 | 637.3 | 728.7 | 756.7 | 371.1 | 332.3 | 536.4 | 157.2 | 64.3 | 55.6 | 83.6 | 81.6 | 144.3 | 182.3 | 89.5 | 93.7 | |
| Other Long-Term Assets | 306.4 | 0.0 | 0.0 | 0.0 | 131.0 | 71.9 | 11.3 | 3.5 | 16.7 | 5.4 | 5.0 | 13.0 | 23.8 | 36.5 | 2.8 | 4.1 | |
| Total Long-Term Assets | 1,295.7 | 1,480.1 | 1,624.4 | 1,452.7 | 781.5 | 691.9 | 874.5 | 525.3 | 170.4 | 126.7 | 153.7 | 160.7 | 236.7 | 288.6 | 164.4 | 177.3 | |
| Total Assets | 2,773.1 | 2,947.7 | 2,942.4 | 3,071.5 | 2,616.2 | 2,137.3 | 1,885.7 | 1,422.3 | 655.3 | 597.5 | 332.3 | 328.0 | 503.3 | 721.1 | 393.3 | 360.8 |
| Long-Term Assets | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Property, Plant & Equipment | 360.7 | 419.7 | 338.6 | 359.1 | 464.6 | 438.1 | 456.5 | 470.9 | 427.2 | 418.5 | |
| Goodwill | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | 63.7 | |
| Intangible Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Long-Term Investments | 578.3 | 594.7 | 619.4 | 637.3 | 523.4 | 432.3 | 629.6 | 728.7 | 811.7 | 838.6 | |
| Other Long-Term Assets | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Long-Term Assets | 1,421.3 | 1,497.3 | 1,440.7 | 1,480.1 | 1,410.6 | 1,295.7 | 1,511.3 | 1,624.4 | 1,533.5 | 1,551.9 | |
| Total Assets | 2,823.5 | 2,678.1 | 2,837.2 | 2,947.7 | 2,960.3 | 2,773.1 | 2,803.8 | 2,942.4 | 2,976.9 | 3,142.5 |
| Current Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 28.7 | 38.2 | 33.8 | 32.7 | 24.3 | 23.6 | 11.6 | 10.9 | 9.6 | 6.6 | 6.4 | 6.4 | 9.3 | 4.4 | 2.0 | 2.0 | |
| Short-Term Debt | 0.0 | 0.0 | 0.0 | 0.0 | -8.7 | 0.0 | 2.7 | 56.8 | 57.5 | 189.1 | 0.0 | 99.3 | 11.8 | 13.2 | 4.9 | 37.7 | |
| Other Current Liabilities | 313.6 | 365.6 | 360.5 | 285.1 | 313.3 | 181.0 | 21.7 | 21.8 | 16.2 | 55.2 | 45.9 | 63.6 | 65.3 | 47.8 | 43.6 | 59.9 | |
| Current Liabilities | 345.7 | 403.8 | 394.3 | 324.4 | 337.6 | 204.7 | 142.7 | 105.5 | 115.2 | 270.6 | 52.3 | 171.9 | 87.9 | 81.7 | 92.3 | 199.9 |
| Current Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 25.3 | 25.8 | 42.8 | 38.2 | 59.3 | 28.7 | 26.1 | 33.8 | 26.5 | 26.0 | |
| Short-Term Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Current Liabilities | 348.4 | 310.3 | 356.3 | 365.6 | 335.0 | 317.0 | 346.9 | 360.5 | 343.4 | 306.8 | |
| Current Liabilities | 373.8 | 336.1 | 399.1 | 403.8 | 394.3 | 345.7 | 373.0 | 394.3 | 376.8 | 339.6 |
| Long-Term Liabilities | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 198.0 | 190.8 | 189.9 | 190.2 | 51.3 | 49.1 | 48.0 | 12.2 | 0.0 | 0.0 | 381.4 | 262.4 | 335.5 | 322.6 | 176.6 | 170.7 | |
| Capital Leases | 198.0 | 190.8 | 189.9 | 190.2 | 51.3 | 49.1 | 50.7 | 12.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Total Liabilities | 653.4 | 703.5 | 678.4 | 583.1 | 405.6 | 258.2 | 199.7 | 134.8 | 370.3 | 508.2 | 436.6 | 442.8 | 437.0 | 424.7 | 302.6 | 589.1 |
| Long-Term Liabilities | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Long-Term Debt | 176.5 | 179.8 | 187.1 | 190.8 | 194.4 | 198.0 | 201.5 | 189.9 | 190.9 | 194.7 | |
| Capital Leases | 176.5 | 179.8 | 187.1 | 190.8 | 194.4 | 198.0 | 201.5 | 189.9 | 190.9 | 194.7 | |
| Def. Tax Liability | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 54.0 | -6.4 | 0.0 | |
| Total Liabilities | 662.8 | 644.5 | 706.2 | 703.5 | 684.9 | 653.4 | 675.7 | 678.4 | 629.3 | 614.5 |
| Total Common Equity | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.2 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | |
| Retained Earnings | -200.0 | -98.6 | -173.4 | -34.2 | -216.5 | -447.6 | -559.4 | -880.4 | -1,829.2 | -1,983.1 | -1,937.0 | -1,767.3 | -1,498.8 | -1,254.0 | -1,106.4 | -1,182.1 | |
| Comprehensive Income | -5.1 | -1.3 | -3.8 | -14.5 | -0.8 | 4.5 | 3.1 | -0.7 | -0.3 | -0.4 | -0.2 | -0.1 | 0.1 | -0.1 | -0.1 | 0.0 | |
| Total Common Equity | 2,119.7 | 2,244.2 | 2,263.9 | 2,488.4 | 2,210.6 | 1,879.1 | 1,686.0 | 1,287.5 | 285.0 | 89.3 | -104.3 | -114.8 | 66.2 | 296.4 | 90.6 | -228.3 |
| Total Common Equity | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | |
| Retained Earnings | -106.1 | -219.5 | -163.3 | -98.6 | -90.3 | -200.0 | -258.9 | -173.4 | -126.0 | 11.2 | |
| Comprehensive Income | 3.6 | 1.3 | 2.0 | -1.3 | 4.0 | -5.1 | -5.2 | -3.8 | -14.0 | -14.4 | |
| Total Common Equity | 2,160.7 | 2,033.5 | 2,131.0 | 2,244.2 | 2,275.4 | 2,119.7 | 2,128.0 | 2,263.9 | 2,347.6 | 2,527.9 |
| Other | TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 198.0 | 190.8 | 189.9 | 190.2 | 51.3 | 49.1 | 50.7 | 12.2 | 0.0 | 189.1 | 381.4 | 361.7 | 347.2 | 335.7 | 181.5 | 208.5 | |
| Book Value | 2,119.7 | 2,244.2 | 2,263.9 | 2,488.4 | 2,210.6 | 1,879.1 | 1,686.0 | 1,287.5 | 285.0 | 89.3 | -104.3 | -114.8 | 66.2 | 296.4 | 90.6 | -228.3 |
| Other | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | 2-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Debt | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Book Value | 2,160.7 | 2,033.5 | 2,131.0 | 2,244.2 | 2,275.4 | 2,119.7 | 2,128.0 | 2,263.9 | 2,347.6 | 2,527.9 |
| Cash Flow From Operating Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 350.0 | 782.6 | 521.3 | 207.8 | 182.3 | 231.1 | 111.8 | 321.0 | 690.1 | 154.2 | -70.2 | -169.7 | -268.5 | -244.8 | -147.6 | 75.7 | -92.3 | |
| Depreciation & Amortization | 26.5 | 29.1 | 28.8 | 25.7 | 20.9 | 13.6 | 9.1 | 8.3 | 7.8 | 1.2 | 1.0 | 1.4 | 2.4 | 3.1 | 5.7 | 6.8 | 10.5 | |
| Stock-Based Compensation | 109.3 | 113.0 | 93.8 | 106.3 | 107.6 | 119.8 | 105.1 | 56.6 | 44.3 | 23.9 | 22.9 | 22.0 | 10.0 | 12.0 | 8.8 | 12.1 | 21.1 | |
| Change Working Capital | -175.7 | -191.2 | -13.5 | -14.0 | -12.8 | -39.0 | -40.1 | 67.1 | -79.8 | -6.9 | 227.3 | -25.8 | -10.3 | -2.3 | -8.6 | -264.9 | -42.3 | |
| Change In Accounts Receivable | -163.5 | -21.4 | -28.0 | -22.6 | 66.8 | -122.3 | -42.5 | 43.7 | -85.5 | -40.8 | -37.0 | -0.6 | -0.9 | 8.5 | 0.0 | 0.0 | 0.0 | |
| Change In Accounts Payable | -3.6 | -50.2 | -21.9 | 53.2 | 25.8 | 55.1 | 51.1 | 44.1 | 0.9 | 3.0 | 0.2 | -1.3 | -13.2 | 8.7 | 6.3 | -5.6 | -9.4 | |
| Change In Inventories | 2.9 | 12.2 | 5.5 | -13.0 | -11.7 | -13.2 | -21.9 | -5.7 | -3.2 | -3.3 | -0.7 | -0.2 | 0.5 | -2.9 | 0.0 | 0.0 | 0.0 | |
| Other Non-cash Items | 373.8 | 24.6 | 129.0 | 140.7 | 125.0 | 28.8 | 7.9 | 2.9 | -2.6 | -10.1 | 13.9 | 30.2 | 33.7 | 33.1 | 19.5 | 88.5 | 6.8 | |
| Cash from Operations | 316.3 | 0.0 | 0.0 | 333.3 | 362.6 | 400.8 | 209.0 | 527.0 | 415.7 | 165.6 | 206.3 | -141.6 | -235.4 | -198.8 | -123.1 | -159.2 | -101.0 |
| Cash Flow From Operating Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 244.5 | 193.6 | 184.8 | 159.6 | 139.9 | 118.0 | 226.1 | 37.3 | 85.5 | 1.0 | |
| Depreciation & Amortization | 6.9 | 7.4 | 7.3 | 7.3 | 7.6 | 7.5 | 7.3 | 6.4 | 6.5 | 6.3 | |
| Stock-Based Compensation | 20.1 | 30.9 | 36.1 | 25.9 | 26.3 | 23.0 | 25.4 | 19.1 | 24.3 | 40.5 | |
| Change Working Capital | -73.0 | 44.8 | -180.3 | 17.2 | 104.2 | 57.7 | -145.9 | -29.5 | 24.4 | -24.7 | |
| Change In Accounts Receivable | 22.8 | -17.4 | -10.7 | -16.1 | 4.2 | 127.0 | -156.0 | -3.2 | 11.2 | -15.5 | |
| Change In Accounts Payable | -12.9 | 17.8 | -63.5 | 8.5 | 2.2 | 26.4 | -16.3 | -34.2 | 46.8 | 0.2 | |
| Change In Inventories | 13.8 | -4.1 | 2.6 | -0.1 | 2.8 | -0.4 | 1.4 | 1.7 | 1.5 | -1.7 | |
| Other Non-cash Items | 134.9 | 13.6 | 1.0 | 1.3 | -37.8 | 65.2 | 6.6 | 35.5 | 3.1 | 117.6 | |
| Cash from Operations | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 10.6 | 117.4 |
| Cash Flow From Investing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -131.8 | 0.0 | -28.4 | -40.5 | -138.5 | -64.2 | -30.3 | -12.8 | -33.3 | -21.1 | -1.7 | -0.4 | -0.5 | -2.2 | -2.7 | -1.0 | -1.8 | |
| Acquisitions | -203.4 | 0.0 | 0.0 | 0.0 | 138.5 | 67.0 | 0.0 | 12.9 | 0.0 | 0.2 | 2.5 | 0.1 | 0.8 | 0.1 | 1.9 | 3.0 | 9.0 | |
| Investments | -508.3 | -610.7 | -927.9 | -902.5 | -1,450.7 | -1,357.2 | -1,070.3 | -1,182.7 | -557.8 | -319.1 | -369.2 | -144.0 | -119.5 | -190.0 | -533.5 | -237.2 | -167.3 | |
| Sales of Investment | 948.3 | 1,022.9 | 877.3 | 1,038.5 | 1,064.8 | 1,378.5 | 969.4 | 608.3 | 293.0 | 376.9 | 153.8 | 178.9 | 252.9 | 325.2 | 310.8 | 182.2 | 140.4 | |
| Other Investing Activities | 306.7 | 0.0 | 0.0 | -122.5 | -138.5 | -67.0 | 0.0 | -12.9 | 0.3 | -1.0 | -1.4 | 15.5 | 12.6 | 11.2 | -36.0 | 1.5 | 0.2 | |
| Cash from Investing | 290.0 | 0.0 | 0.0 | -27.0 | -524.4 | -42.9 | -131.2 | -587.2 | -297.9 | 35.8 | -216.0 | 50.1 | 146.3 | 144.4 | -259.5 | -51.5 | -19.6 |
| Cash Flow From Investing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Capital Expenditure | -1.2 | -1.5 | 0.0 | -3.0 | -4.0 | -8.2 | -6.6 | -9.7 | -13.1 | -93.9 | |
| Acquisitions | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -74.9 | -128.6 | |
| Investments | -154.9 | -189.4 | -101.5 | -186.7 | -305.4 | -375.4 | -108.7 | -138.5 | -78.6 | -182.5 | |
| Sales of Investment | 189.3 | 221.5 | 353.1 | 258.9 | 226.2 | 167.4 | 215.3 | 268.5 | 153.5 | 311.1 | |
| Other Investing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 74.9 | 128.6 | |
| Cash from Investing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 61.7 | 34.7 |
| Cash Flow From Financing Activities | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -185.8 | -7.7 | -4.4 | -11.7 | -13.2 | -4.9 | -8.6 | -39.6 | |
| Debt Issued | 3.3 | 190.8 | 0.9 | -0.2 | 138.9 | 2.2 | -1.7 | 38.6 | 12.2 | -3.3 | -184.6 | 24.2 | 26.1 | 24.7 | 159.1 | -18.3 | 248.0 | |
| Issuance of Common Stock | 39.3 | 0.0 | 0.0 | 33.4 | 23.9 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 145.6 | 75.6 | 0.0 | 203.5 | 181.1 | 3.1 | |
| Repurchase of Common Stock | -891.6 | -947.5 | -652.0 | -550.4 | 23.9 | 24.3 | 0.0 | 22.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | -4.0 | 0.0 | 0.0 | 4.3 | -47.2 | -39.1 | -25.1 | -9.9 | 9.7 | 15.9 | 27.5 | 11.5 | 1.6 | 1.5 | 279.8 | 15.0 | 167.7 | |
| Cash from Financing | -872.3 | 0.0 | 0.0 | -546.1 | 0.6 | -14.8 | -25.1 | 12.6 | 9.7 | -169.9 | 19.8 | 152.7 | 65.5 | -11.7 | 478.4 | 187.5 | 131.3 |
| Cash Flow From Financing Activities | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt Repaid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Debt Issued | 176.5 | -3.4 | -7.3 | -3.7 | -3.6 | -3.6 | -3.4 | 11.5 | -0.9 | -3.8 | |
| Issuance of Common Stock | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | 0.0 | |
| Repurchase of Common Stock | -257.6 | -104.0 | -301.9 | -283.9 | -190.4 | -11.9 | -264.3 | -185.4 | -215.3 | -216.8 | |
| Dividends Paid | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Other Financing Activities | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 9.1 | -2.8 | |
| Cash from Financing | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -206.2 | -219.7 |
| Cash position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | -244.7 | 265.1 | -45.6 | -239.7 | -161.2 | 343.1 | 52.6 | -47.7 | 127.6 | 31.5 | 10.1 | 61.2 | -23.6 | -66.1 | 95.8 | -23.2 | 10.6 | |
| Closing Cash Balance | 157.5 | 482.5 | 217.4 | 263.0 | 502.7 | 663.9 | 320.8 | 268.1 | 315.9 | 183.2 | 151.7 | 141.6 | 80.4 | 104.0 | 170.1 | 74.3 | 97.4 |
| Cash position | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Change in Cash | 106.2 | 169.7 | -19.3 | -33.6 | -41.0 | 59.9 | -61.1 | -3.4 | -133.9 | -67.6 | |
| Closing Cash Balance | 482.5 | 290.8 | 164.4 | 183.8 | 217.4 | 258.3 | 198.5 | 259.6 | 263.0 | 396.9 |
| Free Cash Flow | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 184.5 | 844.3 | 633.8 | 170.4 | 224.2 | 336.6 | 178.6 | 514.1 | 382.4 | 144.5 | 204.6 | -142.0 | -235.9 | -200.9 | -125.9 | -160.2 | -102.9 | |
| Real Free Cash Flow | 75.3 | 731.4 | 540.0 | 64.0 | 116.6 | 216.8 | 73.6 | 457.5 | 338.1 | 120.5 | 181.7 | -164.0 | -245.9 | -213.0 | -134.7 | -172.3 | -124.0 |
| Free Cash Flow | 4-2025 | 3-2025 | 2-2025 | 1-2025 | 4-2024 | 3-2024 | 2-2024 | 1-2024 | 4-2023 | 3-2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 332.4 | 288.8 | 49.0 | 189.0 | 226.3 | 262.1 | 94.7 | 50.6 | -2.6 | 23.5 | |
| Real Free Cash Flow | 312.3 | 258.0 | 12.9 | 163.1 | 199.9 | 239.1 | 69.4 | 31.5 | -26.9 | -17.0 |
Nacenění
Finance
Efektivita
Marže
Dividenda
Ostatní
Nacenění
| Ukazatel | Aktuální | Historické | Konkurence |
|---|---|---|---|
| P/E | 14.9 | 42 | -1.4 |
| P/S | 5 | 12.6 | 9.4 |
| P/B | 5.4 | 14.2 | 5.2 |
| P/FCF | 15.6 | 33.9 | -1.5 |
| Market cap | $10.8 | $7.6 |
P/E (Price to Earnings Ratio) – Poměr ceny akcie k zisku za posledních 12 měsíců. Říká, kolik korun investor zaplatí za 1 korunu zisku. Např.: P/E = 15 znamená, že pokud akcie stojí 15 Kč, firma vydělala 1 Kč za poslední rok.
Finance
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Debt to Assets | 0 % | 31.5 % | 0 % |
| Debt to Income | 22.5 % | 27.4 % | 0 % |
| Debt to Free cash flow | 23.6 % | 268.1 % | 0 % |
| Interest expense percentage | 0 % | -10.3 % | 44.7 % |
| Current ratio | 3.8 | 4.2 | 0 |
Efektivita
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| ROE | 36.2 % | -112.8 % | 0 % |
| ROA | 27.7 % | -4.6 % | 0 % |
| CapEx to Revenue | 0.2 % | 3.3 % | 0 % |
| RaD to Revenue | 0 % | 154.1 % | 0 % |
| ROEM | 2,022,777.7 | 864139.3 |
Marže
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Gross margin | 96.4 % | 96.5 % | 68.7 % |
| Operating margin | 37.6 % | -123.4 % | 35.5 % |
| Net margin | 33.7 % | -155.7 % | 9.5 % |
Dividenda
| Ukazatel | Aktuální | Historické | Srovnání |
|---|---|---|---|
| Dividend yield | 0 % | 0 % | 0 % |
| Dividend payout percentage | 0 % | 0 % | 0 % |
Dividend yield (Dividendový výnos) ukazuje aktuální procentuální výnos z dividend vůči ceně akcie.
Ostatní
| Ukazatel | Aktuální | Historické |
|---|---|---|
| Shares outstanding | 281.9 mil | 252.1 mil |
| Employee count | 1.1 tis | 0.6 tis |
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
Placený obsah
Pro přístup na tuto stránku budete potřebovat placené členství.
Vyzkoušejte placený obsah na akciích: Apple Inc. nebo CEZ, a. s.
